Cluster headache (CH) is, by neurological standards, a relatively common condition that affects about one in 1,000 people, 1 although compared with other more common primary headaches such as migraine 2 it remains rare in practice. CH has been defined in the second edition of the International Classification of Headache Disorders 3 as involving recurrent attacks of severe pain on one side of the head for between 15 and 180 minutes, associated with cranial autonomic features such as lacrimation, conjunctival injection, nasal congestion, or rhinnorhoea (see Table 1 ).
Occipital Nerve Stimulation
Initial interest in the use of ONS to treat headache dates from Weiner and Read, 27 who reported a series of cases of intractable occipital neuralgia responding to ONS. Detailed phenotyping of these cases in association with a functional imaging study demonstrated that almost all patients had chronic migraine. 28 What was remarkable in the ONS patients studied using functional imaging was that the therapy, while effective in terms of pain, did not seem to alter the brain activation of areas considered to be important in migraine. Instead, it changed thalamic processing. Taken together with experimental data collected by the authors of this paper, [29] [30] [31] it was reasoned that ONS may be helpful in selected patients with other primary headache disorders. It seems likely, given that peripheral distribution of the pain does not predict the outcome of stimulation, that ONS has an important central effect on the brain. 32 Six out of the eight patients initially undergoing this procedure had sufficient benefit to recommend the procedure to others and to make it an option for other neuromodulation approaches. 33 Long-term experience over more than two years demonstrated that device dysfunction almost always led to the return of attacks. 34 Thus, it seems unlikely that the useful effect is a prolonged placebo, although much more needs to be done to establish the mechanism of the useful effect.
Central Nervous System ApproachesDeep Brain Stimulation
Recognizing that all invasive treatments bear the risk of severe side effects, international guidelines for patient selection based on expert consensus were published. 35 
Defining the Target Point
The target point for DBS in CH was chosen based on clinical considerations and functional studies, particularly neuroimaging, which revealed the crucial role of the posterior hypothalamic region in CH. 37 Neuroimaging with positron-emission tomography (PET) shed light on the genesis of CH, documenting the link between activation in the hypothalamic gray ipsilateral and pain in CH. 38 These areas are not simply involved in the response to first-division nociceptive pain impulses but are inherent to each syndrome, probably in some permissive or dysfunctional role. 9, 39 Furthermore, using high-resolution structural 3D magnetic resonance images and voxel-based morphometry, a significant structural difference in gray matter density of the hypothalamus was found in patients with CH compared with healthy volunteers. 40 The co-localization of morphometric and functional changes demonstrates the precise anatomical location for a probable central nervous system lesion in CH. Given that this area is involved in circadian rhythms, sleep-wake cycling, 41 and control of the autonomic system, 42 the data suggest a crucial involvement of this hypothalamic area, at least in generation of the acute CH attack. Initially, it was 45 and hemicrania continua. 46 Despite this, a second study found no activation in the hypothalamus in hemicrania continua in a single patient without cranial autonomic features. 47 For DBS the electrode is usually implanted stereotactically in the left posterior hypothalamus/anterior periventricular region of the triangle of Sano, according to the co-ordinates published. 38 This area does not correspond to a specific anatomical entity and there is no consensus as to whether it is part of the posterior hypothalamus or tegmentum, or even the anterior periventricular gray matter. Two sets of stereotactic co-ordinates have been described:
• those published by Leone and colleagues: x=2mm lateral to the midline, y=6mm behind the mid-commissural point, and z=8mm below the commissural plane; 48 and
• the revised co-ordinates published by Franzini et al.:x=2mm lateral, y=3mm posterior, and 5mm inferior to the mid-commissural point. 49 
Electrophysiology
Several studies have obtained single-unit microrecordings from this region in CH patients. All but one 50 were obtained from patients not experiencing an attack and found no particular features in the region.
Recently, local field potentials during a CH attack were performed while surgical implantation of a hypothalamic electrode was ongoing. These potentials showed a significant increase in power during the attack. 50 This appears to be the first report of neuronal activity during a CH, reinforcing neuroimaging data that implicated hypothalamic activation in cluster attack generation.
Technical Functional Imaging Considerations in Cluster Headache
It is important to note that H 2 O-PET has a low spatial (4-5mm) and limited temporal (one minute sample time) resolution. Since the changes in individuals are small, group analyses are required. Furthermore, to achieve a statistically significant result in regional cerebral blood flow, a smoothing kernel of at least 10mm is required. It cannot be overstated that the PET study by Leone et al. is the first time that results from functional imaging have been translated into DBS. Likewise, it needs to be pointed out that these patients have been intractable to medical treatment. 51 However, a failure rate of up to 50% seems quite considerable for an invasive treatment with the theoretical risk of death.
52
Single case studies are possible in principle, 53 and it would be easier to define the individual target point for each patient. 37 This does not change the fact that hypothalamic DBS should be the last option in CH patients. 
Clinical Outcomes from Current Studies

Open Questions
Given that patients who are operated on using peripheral approaches or DBS are medically intractable and consequently highly disabled, these approaches can substantially restore function. However, there are many issues to be resolved, such as how to design placebo stimuli in ONS and how to better identify the target in DBS. DBS imaging methods seem an obvious way forward, although the authors have been studying a human brain from a patient with CH and it could be contended that imaging pathological reconstructions may be an even better approach.
Whatever is said about various techniques, while CH is a devastating disease, primum non nocere. n
